Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.

Biotech Giants' R&D Surge: A Decade of Innovation

__timestampAmicus Therapeutics, Inc.Neurocrine Biosciences, Inc.
Wednesday, January 1, 20144762400046425000
Thursday, January 1, 20157694300081491000
Friday, January 1, 201610479300094291000
Sunday, January 1, 2017149310000121827000
Monday, January 1, 2018270902000160524000
Tuesday, January 1, 2019286378000200000000
Wednesday, January 1, 2020308443000275000000
Friday, January 1, 2021272049000328100000
Saturday, January 1, 2022276677000463800000
Sunday, January 1, 2023152381000565000000
Monday, January 1, 2024731100000
Loading chart...

Unlocking the unknown

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Amicus Therapeutics, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking in 2023 with a remarkable 565% increase compared to 2014. Meanwhile, Amicus Therapeutics saw a 220% rise in R&D spending over the same period, with a notable peak in 2020. This trend underscores the growing emphasis on developing groundbreaking therapies.

The data reveals a strategic shift in priorities, with both companies allocating substantial resources to research, aiming to lead the charge in innovative treatments. As the biotech landscape evolves, these investments are crucial for maintaining a competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025